Metraipolis › archive › dc_addf72769603

Fc-engineering for improved cancer immunotherapy — Europe PMC PMID:42621748

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42621748
DOI
10.1042/bst20250554
License (as archived)
solo-consultazione
Archived
2026-10-08T09:10:08.571Z
SHA-256 of the archived text
135b6c126dd39ae6167e8ec11aaabe0b5c1b0ff6a9e79306c67083a69f4b603d
Stable URL of this page
https://metraipolis.com/documento/dc_addf72769603

How to cite

Fc-engineering for improved cancer immunotherapy — Europe PMC PMID:42621748 — Europe PMC (en), https://europepmc.org/article/MED/42621748 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_addf72769603 (Metraipolis archive dc_addf72769603, sha256 135b6c126dd39ae6167e8ec11aaabe0b5c1b0ff6a9e79306c67083a69f4b603d)
BibTeX
@misc{dcaddf72769603,
  title = {Fc-engineering for improved cancer immunotherapy — Europe PMC PMID:42621748},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42621748},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_addf72769603; sha256 135b6c126dd39ae6167e8ec11aaabe0b5c1b0ff6a9e79306c67083a69f4b603d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42621748. Agents can read the archived copy with the MCP tool read_document.